Back to top

Analyst Blog

Genomic Health (GHDX - Analyst Report), an oncology based biotech company, presented the results from 6 studies of the Oncotype DX breast cancer test at the San Antonio Breast Cancer Symposium earlier this month. The company has been recording robust revenue growth over the last few quarters banking on its flagship product, Oncotype DX breast cancer test.

This test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early stage breast cancer patients. Genomic Health believes that these latest studies will fortify the impact of this test providing physicians with better treatment options in node-negative and node-positive invasive early-stage breast cancer. Also, two of these studies have proved the cost effectiveness of this test in invasive breast cancer and ductal carcinoma in situ (DCIS).

Genomic Health has undertaken several studies to expand the use of Oncotype DX. In September 2012, the company announced positive results from a large clinical validation study of its biopsy-based prostate cancer test. Accordingly, the commercial launch of the Oncotype DX prostate cancer test is expected by the first half of 2013.

In the same month, the company also announced positive data supporting the extended use of the Oncotype DX tests in optimizing treatment decisions for breast and colon cancer patients at various stages of the disease. Successful development of the test will be of immense benefit to a huge patient population as DCIS is an increasingly detected sub-group of breast cancer, and more than 45,000 patients are diagnosed with DCIS each year in the U.S. alone.

The number of Oncotype DX tests delivered by Genomic Health, during the most recent quarter, increased 7% year over year with deeper penetration in new markets. We encouragingly note that, in the quarter, the company established reimbursement agreements with three additional state Medicaid programs for node-negative breast cancer patients. Although the colon cancer test, launched in January 2010, is yet to make a significant contribution to the top line, the situation is gradually improving with Medicare’s decision to cover the Oncotype DX colon cancer test. We believe that favorable data from the worldwide studies might help the company in securing reimbursements.

We are also encouraged by the company’s increasing focus on the international market. In the last reported quarter, the company secured incremental international reimbursements for the Oncotype DX breast cancer test in France, Greece, Kuwait and Spain. Further, Genomic Health is conducting several studies to expand its portfolio or increase the acceptance of the tests.

However, the expansion plans involve higher expenses, which in turn will adversely affect the margins. Additionally, the company’s newly formed subsidiary InVitae Corporationwill require substantial investment. The company faces tough competition from players such as Myriad Genetics (MYGN - Analyst Report), among others.

Currently, Genomic Health retains a Zacks #3 Rank (short-term ‘Hold’ rating). We have a ‘Neutral’ recommendation on the stock over the long term.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%